93 related articles for article (PubMed ID: 17012877)
1. Development of an approach for the laboratory toxicological evaluation of Bordetella pertussis adenylate cyclase genetic toxoid constructs as multipurpose vaccines.
Prior S; Corbel MJ; Xing DK
Hum Vaccin; 2005; 1(4):151-9. PubMed ID: 17012877
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Adenylate Cyclase Toxoid Antigen in Acellular Pertussis Vaccines by Using a Bordetella pertussis Challenge Model in Mice.
Boehm DT; Hall JM; Wong TY; DiVenere AM; Sen-Kilic E; Bevere JR; Bradford SD; Blackwood CB; Elkins CM; DeRoos KA; Gray MC; Cooper CG; Varney ME; Maynard JA; Hewlett EL; Barbier M; Damron FH
Infect Immun; 2018 Oct; 86(10):. PubMed ID: 30012638
[No Abstract] [Full Text] [Related]
3. Adjuvanticity of native and detoxified adenylate cyclase toxin of Bordetella pertussis towards co-administered antigens.
Macdonald-Fyall J; Xing D; Corbel M; Baillie S; Parton R; Coote J
Vaccine; 2004 Oct; 22(31-32):4270-81. PubMed ID: 15474718
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of adenyl cyclase toxin constructs from Bordetella pertussis as candidate vaccine components in an in vitro model of complement-dependent intraphagocytic killing.
Prior S; Fleck RA; Gillett ML; Rigsby PR; Corbel MJ; Stacey GN; Xing DK
Vaccine; 2006 May; 24(22):4794-803. PubMed ID: 16675078
[TBL] [Abstract][Full Text] [Related]
5. Efficient Ex vivo stimulation of Mycobacterium tuberculosis-specific T cells by genetically detoxified Bordetella pertussis adenylate cyclase antigen toxoids.
Wilkinson KA; Simsova M; Schölvinck E; Sebo P; Leclerc C; Vordermeier HM; Dickson SJ; Brown JR; Davidson RN; Pasvol G; Levin M; Wilkinson RJ
Infect Immun; 2005 May; 73(5):2991-8. PubMed ID: 15845506
[TBL] [Abstract][Full Text] [Related]
6. Protective role of adenylate cyclase in the context of a live pertussis vaccine candidate.
Lim A; Ng JK; Locht C; Alonso S
Microbes Infect; 2014 Jan; 16(1):51-60. PubMed ID: 24140230
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant and protective properties of native and recombinant Bordetella pertussis adenylate cyclase toxin preparations in mice.
Hormozi K; Parton R; Coote J
FEMS Immunol Med Microbiol; 1999 Apr; 23(4):273-82. PubMed ID: 10225286
[TBL] [Abstract][Full Text] [Related]
8. Effect of different forms of adenylate cyclase toxin of Bordetella pertussis on protection afforded by an acellular pertussis vaccine in a murine model.
Cheung GY; Xing D; Prior S; Corbel MJ; Parton R; Coote JG
Infect Immun; 2006 Dec; 74(12):6797-805. PubMed ID: 16982827
[TBL] [Abstract][Full Text] [Related]
9. Adenylate cyclase toxin-hemolysin relevance for pertussis vaccines.
Sebo P; Osicka R; Masin J
Expert Rev Vaccines; 2014 Oct; 13(10):1215-27. PubMed ID: 25090574
[TBL] [Abstract][Full Text] [Related]
10. The adenylate cyclase of Bordetella pertussis: a vector to target antigen presenting cells.
El Azami El Idrissi M; Ladant D; Leclerc C
Toxicon; 2002 Dec; 40(12):1661-5. PubMed ID: 12457876
[No Abstract] [Full Text] [Related]
11. Bordetella pertussis adenylate cyclase toxin modulates innate and adaptive immune responses: distinct roles for acylation and enzymatic activity in immunomodulation and cell death.
Boyd AP; Ross PJ; Conroy H; Mahon N; Lavelle EC; Mills KH
J Immunol; 2005 Jul; 175(2):730-8. PubMed ID: 16002668
[TBL] [Abstract][Full Text] [Related]
12. Induction of a polarized Th1 response by insertion of multiple copies of a viral T-cell epitope into adenylate cyclase of Bordetella pertussis.
Dadaglio G; Moukrim Z; Lo-Man R; Sheshko V; Sebo P; Leclerc C
Infect Immun; 2000 Jul; 68(7):3867-72. PubMed ID: 10858196
[TBL] [Abstract][Full Text] [Related]
13. Delivery of multiple epitopes by recombinant detoxified adenylate cyclase of Bordetella pertussis induces protective antiviral immunity.
Fayolle C; Osickova A; Osicka R; Henry T; Rojas MJ; Saron MF; Sebo P; Leclerc C
J Virol; 2001 Aug; 75(16):7330-8. PubMed ID: 11462005
[TBL] [Abstract][Full Text] [Related]
14. Toxicity tests on native and recombinant Bordetella pertussis adenylate cyclase toxin preparations.
Hormozi K; Parton R; Coote J
Dev Biol Stand; 1999; 101():147-54. PubMed ID: 10566788
[TBL] [Abstract][Full Text] [Related]
15. Formulation of the adenylate cyclase toxin of Bordetella pertussis as protein-coated microcrystals.
Khosravani A; Parker MC; Parton R; Coote J
Vaccine; 2007 May; 25(22):4361-7. PubMed ID: 17434242
[TBL] [Abstract][Full Text] [Related]
16. Functional and structural studies on different forms of the adenylate cyclase toxin of Bordetella pertussis.
Cheung GY; Kelly SM; Jess TJ; Prior S; Price NC; Parton R; Coote JG
Microb Pathog; 2009 Jan; 46(1):36-42. PubMed ID: 18992319
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant effects of adenylate cyclase toxin of Bordetella pertussis after intranasal immunisation of mice.
Orr B; Douce G; Baillie S; Parton R; Coote J
Vaccine; 2007 Jan; 25(1):64-71. PubMed ID: 16916566
[TBL] [Abstract][Full Text] [Related]
18. Targeted mutations that ablate either the adenylate cyclase or hemolysin function of the bifunctional cyaA toxin of Bordetella pertussis abolish virulence.
Gross MK; Au DC; Smith AL; Storm DR
Proc Natl Acad Sci U S A; 1992 Jun; 89(11):4898-902. PubMed ID: 1594590
[TBL] [Abstract][Full Text] [Related]
19. Delivery of CD8(+) T-cell epitopes into major histocompatibility complex class I antigen presentation pathway by Bordetella pertussis adenylate cyclase: delineation of cell invasive structures and permissive insertion sites.
Osicka R; Osicková A; Basar T; Guermonprez P; Rojas M; Leclerc C; Sebo P
Infect Immun; 2000 Jan; 68(1):247-56. PubMed ID: 10603395
[TBL] [Abstract][Full Text] [Related]
20. Direct delivery of the Bordetella pertussis adenylate cyclase toxin to the MHC class I antigen presentation pathway.
Guermonprez P; Ladant D; Karimova G; Ullmann A; Leclerc C
J Immunol; 1999 Feb; 162(4):1910-6. PubMed ID: 9973458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
